{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:41:06Z","timestamp":1790480466243,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P20 GM130423"],"award-info":[{"award-number":["P20 GM130423"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK113111"],"award-info":[{"award-number":["R01 DK113111"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 DK126126"],"award-info":[{"award-number":["U54 DK126126"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1053\/j.akdh.2022.12.009","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T20:54:00Z","timestamp":1682110440000},"page":"285-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Biomarkers in Polycystic Kidney Disease: Are We There?"],"prefix":"10.1053","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1776-2533","authenticated-orcid":false,"given":"Alan S.L.","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas P.","family":"Landsittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.akdh.2022.12.009_bib1","series-title":"BEST (Biomarkers, EndpointS, and other Tools) Resource","year":"2016"},{"issue":"7","key":"10.1053\/j.akdh.2022.12.009_bib2","doi-asserted-by":"crossref","first-page":"8966","DOI":"10.3390\/s120708966","article-title":"Study designs and statistical analyses for biomarker research","volume":"12","author":"Gosho","year":"2012","journal-title":"Sensors"},{"issue":"5","key":"10.1053\/j.akdh.2022.12.009_bib3","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2018.12.023","article-title":"Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease","volume":"95","author":"Yu","year":"2019","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.akdh.2022.12.009_bib4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. Research support, N.I.H., Extramural","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"20","key":"10.1053\/j.akdh.2022.12.009_bib5","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.akdh.2022.12.009_bib6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2022.12.009_bib7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2017.09.027","article-title":"Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in autosomal dominant polycystic kidney disease","volume":"93","author":"Yu","year":"2018","journal-title":"Kidney Int"},{"issue":"15","key":"10.1053\/j.akdh.2022.12.009_bib8","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138724","article-title":"The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD","volume":"5","author":"Lavu","year":"2020","journal-title":"JCI Insight"},{"issue":"3","key":"10.1053\/j.akdh.2022.12.009_bib9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2215\/CJN.03250410","article-title":"Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease","volume":"6","author":"Torres","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.akdh.2022.12.009_bib10","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/ndt\/gfv422","article-title":"Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.akdh.2022.12.009_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ekir.2017.10.004","article-title":"Urinary biomarkers to identify autosomal dominant polycystic kidney disease patients with a high likelihood of disease progression","volume":"3","author":"Messchendorp","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.akdh.2022.12.009_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1159\/000508051","article-title":"KIM-1 and kidney disease progression in autosomal dominant polycystic kidney disease: HALT-PKD results","volume":"51","author":"Griffin","year":"2020","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2022.12.009_bib13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ekir.2021.01.004","article-title":"Prognostic value of Fibroblast growth factor 23 in autosomal dominant polycystic kidney disease","volume":"6","author":"El Ters","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"7","key":"10.1053\/j.akdh.2022.12.009_bib14","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.2018121227","article-title":"Soluble urokinase plasminogen activator receptor and decline in kidney function in autosomal dominant polycystic kidney disease","volume":"30","author":"Hayek","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2022.12.009_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233213","article-title":"Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease","volume":"15","author":"Dekker","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1053\/j.akdh.2022.12.009_bib16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000524851","article-title":"Change in urinary Myoinositol\/citrate ratio Associates with progressive loss of renal function in ADPKD patients","volume":"53","author":"Dekker","year":"2022","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2022.12.009_bib17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","article-title":"Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort","volume":"61","author":"Boertien","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.akdh.2022.12.009_bib18","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000382081","article-title":"Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?","volume":"41","author":"Casteleijn","year":"2015","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2022.12.009_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.11.044","article-title":"Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease","volume":"96","author":"Gansevoort","year":"2019","journal-title":"Kidney Int"},{"key":"10.1053\/j.akdh.2022.12.009_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.peptides.2013.08.007","article-title":"Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease","volume":"49","author":"Lacquaniti","year":"2013","journal-title":"Peptides"},{"issue":"2","key":"10.1053\/j.akdh.2022.12.009_bib21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2215\/CJN.10470620","article-title":"Use of the urine-to-plasma urea ratio to predict ADPKD progression","volume":"16","author":"Heida","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2022.12.009_bib22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.kint.2020.04.053","article-title":"Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease","volume":"98","author":"Kramers","year":"2020","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.akdh.2022.12.009_bib23","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2215\/CJN.12821216","article-title":"Fibroblast growth factor 23 and kidney disease progression in autosomal dominant polycystic kidney disease","volume":"12","author":"Chonchol","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2022.12.009_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/ndt\/gfw243","article-title":"Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression","volume":"32","author":"Pejchinovski","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.akdh.2022.12.009_bib25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.kint.2020.02.008","article-title":"Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease","volume":"98","author":"Magayr","year":"2020","journal-title":"Kidney Int"},{"key":"10.1053\/j.akdh.2022.12.009_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1471-2369-13-93","article-title":"Urinary N-acetyl-beta-D glucosaminidase as a surrogate marker for renal function in autosomal dominant polycystic kidney disease: 1 year prospective cohort study","volume":"13","author":"Park","year":"2012","journal-title":"BMC Nephrol"},{"issue":"10","key":"10.1053\/j.akdh.2022.12.009_bib27","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1681\/ASN.2011010084","article-title":"Macrophages promote cyst growth in polycystic kidney disease. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't","volume":"22","author":"Karihaloo","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2022.12.009_bib28","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/ki.2012.446","article-title":"Macrophages promote polycystic kidney disease progression. research support, N.I.H., extramural research support, Non-U.S. Gov't","volume":"83","author":"Swenson-Fields","year":"2013","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2022.12.009_bib29","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.kint.2018.06.025","article-title":"CD8(+) T cells modulate autosomal dominant polycystic kidney disease progression","volume":"94","author":"Kleczko","year":"2018","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2022.12.009_bib30","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1046\/j.1523-1755.2001.00065.x","article-title":"Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Research Support, Non-U.S. Gov't","volume":"60","author":"Cowley","year":"2001","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2022.12.009_bib31","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/ndt\/gfw060","article-title":"Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease","volume":"32","author":"Grantham","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1053\/j.akdh.2022.12.009_bib32","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ki.2011.465","article-title":"Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Research support, N.I.H., extramural","volume":"81","author":"Parikh","year":"2012","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.akdh.2022.12.009_bib33","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"issue":"11","key":"10.1053\/j.akdh.2022.12.009_bib34","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41581-018-0051-1","article-title":"Metabolism and mitochondria in polycystic kidney disease research and therapy","volume":"14","author":"Padovano","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.akdh.2022.12.009_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s40620-022-01361-6","article-title":"Kynurenines in polycystic kidney disease","author":"Klawitter","year":"2022","journal-title":"J Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2022.12.009_bib36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12882-019-1249-6","article-title":"Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course","volume":"20","author":"Kim","year":"2019","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2022.12.009_bib37","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1038\/s41598-021-84609-8","article-title":"Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease","volume":"11","author":"Baliga","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1053\/j.akdh.2022.12.009_bib38","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.11311111","article-title":"Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment","volume":"7","author":"Zittema","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.akdh.2022.12.009_bib39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fendo.2017.00120","article-title":"Role of the vasopressin\/apelin balance and potential Use of Metabolically stable apelin Analogs in water metabolism disorders","volume":"8","author":"Flahault","year":"2017","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1053\/j.akdh.2022.12.009_bib40","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2022.12.009_bib41","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/1744-9987.12412","article-title":"Evaluation of Fibrosis markers: apelin and Transforming growth factor-beta1 in autosomal dominant polycystic kidney disease patients","volume":"20","author":"Kocer","year":"2016","journal-title":"Ther Apher Dial"},{"issue":"13","key":"10.1053\/j.akdh.2022.12.009_bib42","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.3390\/ijms22136885","article-title":"Coregulation analysis of mechanistic biomarkers in autosomal dominant polycystic kidney disease","volume":"22","author":"Leierer","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1053\/j.akdh.2022.12.009_bib43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrneph.2012.139","article-title":"Polycystic kidney disease: an early urea-selective urine-concentrating defect in ADPKD","volume":"8","author":"Bankir","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2022.12.009_bib44","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/1740774510368574","article-title":"Predictive biomarker validation in practice: lessons from real trials","volume":"7","author":"Mandrekar","year":"2010","journal-title":"Clin Trials"},{"issue":"4","key":"10.1053\/j.akdh.2022.12.009_bib45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ekir.2016.08.001","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the TEMPO 3:4 clinical trial","volume":"1","author":"Irazabal","year":"2016","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1053\/j.akdh.2022.12.009_bib46","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ndt\/gfx188","article-title":"Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial","volume":"33","author":"Cornec-Le Gall","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.akdh.2022.12.009_bib47","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/ndt\/gfq018","article-title":"Statistical methods for the assessment of prognostic biomarkers (Part I): discrimination","volume":"25","author":"Tripepi","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"10.1053\/j.akdh.2022.12.009_bib48","first-page":"S83","article-title":"Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests","volume":"29","author":"Florkowski","year":"2008","journal-title":"Clin Biochem Rev"},{"key":"10.1053\/j.akdh.2022.12.009_bib49","doi-asserted-by":"crossref","first-page":"103496","DOI":"10.1016\/j.jbi.2020.103496","article-title":"A practical perspective on the concordance index for the evaluation and selection of prognostic time-to-event models","volume":"108","author":"Longato","year":"2020","journal-title":"J Biomed Inform"},{"issue":"1","key":"10.1053\/j.akdh.2022.12.009_bib50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/oxfordjournals.aje.a113284","article-title":"A review of goodness of fit statistics for use in the development of logistic regression models","volume":"115","author":"Lemeshow","year":"1982","journal-title":"Am J Epidemiol"},{"key":"10.1053\/j.akdh.2022.12.009_bib51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41512-018-0037-2","article-title":"Quantifying the added value of new biomarkers: how and how not","volume":"2","author":"Cook","year":"2018","journal-title":"Diagn Progn Res"},{"key":"10.1053\/j.akdh.2022.12.009_bib52","series-title":"The statistical evaluation of medical tests for classification and prediction","author":"Pepe","year":"2003"},{"issue":"11","key":"10.1053\/j.akdh.2022.12.009_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012799","article-title":"STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration","volume":"6","author":"Cohen","year":"2016","journal-title":"BMJ Open"},{"issue":"3","key":"10.1053\/j.akdh.2022.12.009_bib54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/bjs.9736","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"102","author":"Collins","year":"2015","journal-title":"Br J Surg"},{"issue":"20","key":"10.1053\/j.akdh.2022.12.009_bib55","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/djn326","article-title":"Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design","volume":"100","author":"Pepe","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"10.1053\/j.akdh.2022.12.009_bib56","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.109.192278","article-title":"Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the\u00a0American Heart Association","volume":"119","author":"Hlatky","year":"2009","journal-title":"Circulation"},{"issue":"158","key":"10.1053\/j.akdh.2022.12.009_bib58","first-page":"49244","article-title":"Qualification of biomarker-total kidney volume in studies for treatment of autosomal dominant polycystic kidney disease; draft guidance for Industry","volume":"80","year":"2015","journal-title":"Fed Regist"},{"issue":"3","key":"10.1053\/j.akdh.2022.12.009_bib59","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp Biol Med (Maywood)"},{"issue":"4","key":"10.1053\/j.akdh.2022.12.009_bib60","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/j.ajkd.2018.11.001","article-title":"Addressing the need for clinical trial end points in autosomal dominant polycystic kidney disease: a report from the polycystic kidney disease outcomes Consortium (PKDOC)","volume":"73","author":"Smith","year":"2019","journal-title":"Am J Kidney Dis"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813922000349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813922000349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:11:44Z","timestamp":1762650704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813922000349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2949813922000349"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2022.12.009","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers in Polycystic Kidney Disease: Are We There?","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2022.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}